trametinib trametinib trametinib, sold under the brand name mekinist among others, is an anticancer medication used for the treatment of melanoma. it is a mek inhibitor drug with anti-cancer activity. it inhibits mek1 and mek2. it is taken by mouth. trametinibclinical datatrade namesmekinistother namesgsk1120212ahfs/drugs.commonographmedlineplusa613040license data eu ema: by inn us dailymed: trametinib routes ofadministrationby mouthatc codel01ee01 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only eu: rx-only identifiers iupac name n-(3-phenyl)acetamide cas number871700-17-3pubchem cid11707110drugbankdb08911chemspider9881833unii33e86k87qnkeggd10175chebichebi:75998chemblchembl2103875comptox dashboard (epa)dtxsid901007381 echa infocard100.158.135 chemical and physical dataformulac26h23fin5o4molar mass615.404 g·mol−13d model (jsmol)interactive image smiles ic1ccc(c(f)c1)n\c3=c\2/c(=o)n(c(=o)n(c/2=c(\c(=o)n3c)c)c4cccc(nc(=o)c)c4)c5cc5 inchi inchi=1s/c26h23fin5o4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30h,8-9h2,1-3h3,(h,29,34)key:liryphyghxzjbz-uhfffaoysa-n the most common side effects include rash, diarrhea, tiredness, peripheral edema (swelling, especially of ankles and feet), nausea and acneiform dermatitis (acne-like inflammation of the skin). when taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash. in may 2013, trametinib was approved as a single-agent by the us food and drug administration for the treatment of people with v600e mutated metastatic melanoma. it was approved for medical use in the european union in june 2014. history clinical trial data demonstrated that resistance to single-agent trametinib often occurs within 6 to 7 months. to overcome this, trametinib was combined with the braf inhibitor dabrafenib. as a result of this research, on 8 january 2014, the fda approved the combination of dabrafenib and trametinib for the treatment of patients with braf v600e/k-mutant metastatic melanoma. on 1 may 2018, the fda approved the combination dabrafenib/trametinib as an adjuvant treatment for braf v600e-mutated, stage iii melanoma after surgical resection based on the results of the combi-ad phase 3 study, making it the first oral chemotherapy regimen that prevents cancer relapse for node positive, braf-mutated melanoma. research trametinib had good results for metastatic melanoma carrying the braf v600e mutation in a phase iii clinical trial. in this mutation, the amino acid valine (v) at position 600 within the braf protein has become replaced by glutamic acid (e) making the mutant braf protein constitutively active.